Cigna Group (NYSE:CI) 株価情報

THE CIGNA GROUP

Cigna

Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.

The Cigna Group

Citizens, Inc. Class A Common Stock ($1.00 Par)

Citizens Inc

CHINA MENGNIU DAIRY CO by China Mengniu Dairy Co., Ltd.

China Mengniu Dairy Co Ltd

CHINA MENGNIU DARY UN/ADR by China Mengniu Dairy Co., Ltd.

CHAMPION IRON LTD by Champion Iron Limited

Champion Iron Ltd

CHINA SCORE INC by China Score, Inc.

BanColombia SA

COMML INTL BK S/ADR by Commercial International Bank Ltd.

Commercial International Bank (Egypt) CIB

CIB MARINE BANCSHARES by CIB Marine Bancshares, Inc.

CIB Marine Bancshares Inc

COMMUTY INV BANCORP INC by Community Investors Bancorp, Inc.

Community Investors Bancorp Inc

First Trust NASDAQ Cybersecurity ETF

CIBL Inc

CION Investment Corporation 7.50% Notes due 2029

CHINA CONSTR BANK H by China Construction Bank Corp.

China Construction Bank Corp

CHINA CONSTR BK UNSP/ADR by China Construction Bank Corp.

SMS ALTERNATIVES INC by SMS Alternatives Inc.

SMS Alternatives Inc

COSCO SHIPPING HLDGS CO by COSCO SHIPPING Holdings Co Ltd.

COSCO SHIPPING Holdings Co Ltd

COSCO SHP HLDG UNSP/ADR by COSCO SHIPPING Holdings Co Ltd.

CONCEPCION INDUSTRIAL CRP by CONCEPCION INDUSTRIAL CORP

Victory Portfolios II VictoryShares International High Div Volatility Wt

CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD.

Ciena Corp

CHieru Co Ltd

CORPORACION INTERAMER B by Corporacion Intramericano Entretenimiento S.A.

Corporacion Interamericana de Entretenimiento SAB de CV

MFS Intermediate High Income Fund Common Stock

Mfs Intermediate High Income Fund

Cipher Mining Inc

Comp En De Mn Cemig ADS American Depositary Shares

Cia Energetica DE Minas Gerais - Cemig

Comp En De Mn Cemig ADS American Depositary Receipts

Colliers International Group Inc. - Subordinate Voting Shares

Colliers International Group Inc

CI Games SE

CHINA MERCHANTS BK CO H by China Merchants Bank Co., Ltd.

China Merchants Bank Co Ltd

CHINA MRCHNTS BK UNSP/ADR by China Merchants Bank Co., Ltd.

CB INDUS PRODUCT HLDG BHD by CB Industrial Product Holding BHD

BlackRock Enhanced Large Cap Core Fund, Inc. Common Stock

Blackrock Enhanced Cap&Inc Fund, Inc

CITIC SECURITIES CO LTD H by Citic Securities Co., Ltd.

CITIC Securities Co Ltd

CITIC SECURITIES UNSP/ADR by Citic Securities Co., Ltd.

TIANCI INTERNATIONAL INC by Tianci International Inc.

Tianci International Inc

Credit Suisse Asset Management Income Fund, Inc. Common Stock

Credit Suisse Asset Mgmt Income Fund Inc

VictoryShares International Volatility Wtd ETF

CHINA LIFE INS CO H SHS by China Life Insurance Company Limited

China Life Insurance Co Ltd

CAROLINA MILLS INC by Carolina Mills, Inc.

Chimera Investment Corporation Common Stock

Chimera Investment Corp

CIMB GROUP HLDGS BHD ORD by CIMB Group Holdings BHD

CIMB Group Holdings Bhd

CIMC ENRIC HLDGS LTD ORD by CIMC Enric Holdings Ltd.

CIMC Enric Holdings Ltd

Chimera Investment Corporation 9.000% Senior Notes due 2029

Chimera Investment Corporation 9.250% Senior Notes due 2029

CIMAREX ENERGY 8 1/8 PFD by Cimarex Energy Co.

Chimera Investment Corporation 8.00% Series A Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

CHINA INDUSTRIAL GRP INC by China Industrial Group, Inc.

Cincinnati Financial Corporation - Common Stock

Cincinnati Financial Corp

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

CHINA TAIPING INS HLD ORD by China Taiping Insurance Holdings Co Ltd.

China Taiping Insurance Holdings Co Ltd

CI&T Inc

CRUCIAL INNOVATIONS CORP by CRUCIAL INNOVATIONS CORP.

City Office REIT Inc

CREATE MEDIC CO LTD by Create Medic Company Ltd.

Create Medic Co Ltd

CION Invt Corp

CENTRAL IRON ORE LIMITED by CENTRAL IRON ORE LIMITED

Central Iron Ore Ltd

Cielo SA ADR

City Office REIT, Inc. 6.625% Series A Cumulative Redeemable Preferred Stock

CORRELATE ENERGY CORP by Correlate Energy Corp.

Correlate Energy Corp

JPMorgan Exchange-Traded Fund Trust Sustainable Consumption ETF

Cirus Foundation

CirTran Corp

Ciscom Corp

CHINA STEEL CP S/ADR 144A by China Steel Corp.

China Steel Corp

CISO Global Inc

C3is Inc

CHINA STEEL CORP S/GDR by China Steel Corp.

COSCO SHIPPING DEV CO LTD by Cosco Shipping Development Co Ltd.

Cosco Shipping Development Co Ltd

COSCO SHIP DEV UNSP/ADR by Cosco Shipping Development Co Ltd.

CARTICA ACQUISITION CORP L ASHS

CARTICA ACQUISITION CORP USD 1 CL A SHS & 1/2 RED WT EXP

CARTICA ACQUISITION CORP RED WTS

CRITICAL INFRASTUCTRE TCH by Critical Infrastructure Technologies Ltd.

Critical Infrastructure Technologies Ltd

AVALON CORRECTIONAL INC by Avalon Correctional Services, Inc.

Manchester City Fan Token

CITIZENS BANCSHARES CP SC by Citizens Bancshares Corp South Carolina

Citizens Bancshares Corp

Civilization

Civista Bancshares Inc

Civitas Resources Inc

Civitas Resources Inc Warrants (20/01/2026)

Civitas Resources Inc Warrants (20/01/2025)

CTR INVTS&CNSLTNG INC by CTR Investments & Consulting, Inc.

CTR Investments & Consulting Inc

CHINA INDL WASTE MGMT INC by China Industrial Waste Management, Inc.

China Industrial Waste Management Inc

CITZNS FINCL CORP W VA by Citizens Financial Corp. (WV)

Citizens Financial Corp WV

Compx International Inc

CaixaBank SA

CI Financial Corp

COMPASS EMP FDS TR DEVELOPED 500 ENHANCED VOLATILITY WEIGHTED INDEX ETF

CITZNS HOLDINGS CO MISS by Citizens Holding Co.

Citizens Holding Co

In September, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark, Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts, and UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">price of insulin medications</a>.
The&nbsp;complaint&nbsp;accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">prescriptions in the U.S</a>.
The FTC is now pausing after the agency submitted <a href="https://www.ftc.gov/system/files/ftc_gov/pdf/d9437_2025.04.01_commorderstayingadjudication.pdf" target="_blank" rel="noreferrer noopener">an order</a> seeking an administrative stay in the case.
Also Read:<a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43010888/ftc-says-unitedhealth-cvs-cigna-make-billions-via-pbms-on-specialty-drugs" rel="noreferrer noopener"> FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs</a>
The agency does not cite any sitting commissioners who can join the proceedings. The two sitting commissioners, Republicans Andrew Ferguson and Melissa Holyoak, <a href="https://www.benzinga.com/government/24/10/41172976/texas-attorney-general-sues-insulin-manufacturers-and-pharmacy-benefit-managers-over-price-fixing-co" target="_blank" rel="noreferrer noopener">have recused themselves</a>.
According to the order filed this week, the stay will remain in place for at least 105 days. The courts also set an evidentiary hearing for 225 days after the stay lifts.
Reuters notes that of its five sitting commissioners, two were fired, two were removed from the case, and one resigned when Trump took office.
Several state and local governments also filed lawsuits against drug companies and pharmacy benefit managers, accusing them <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40560002/governments-suing-pharmacy-benefit-managers-over-insulin-prices-have-long-benefited-from-their-r" rel="noreferrer noopener">of inflating insulin prices</a>.
In November 2024, the FTC faced legal challenges from three competing pharmacy-benefit managers over its attempt to restrict their ability to negotiate drug prices for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system" rel="noreferrer noopener">health plan sponsors</a>.
The PBMs argue that this action seeks to upend current drug rebate contracts and disrupt long-standing practices, all while expanding the FTC&#8217;s authority beyond traditional limits.
The companies also&nbsp;contend&nbsp;that the administrative proceeding violates constitutional principles by lacking independent judicial oversight and claim that the FTC&#8217;s approach could result in significant and irreparable injury.
Price Action: CI stock is down 1.13% at $328.16, UNH stock is up 0.04% at $523.40, and CVS stock is down 0.85% at $67.49&nbsp;during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44614073/sportradars-big-bet-on-sports-data-analyst-raises-2026-forecast-sees-major-growth-in-live-betting" target="_blank" rel="noreferrer noopener">Sportradar&#8217;s Bets Big On Sports Data, Analyst Says Company Has Favorable Setup</a></li>
</ul>
Image: Shutterstock

Large Cap

News

Health Care

Legal

General

FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth's PBMs Amid Commissioner Shortage

Financial giants have made a conspicuous bullish move on Cigna Group. Our analysis of options history for Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) revealed 14 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 42% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $814,022, and 2 were calls, valued at $71,613.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $260.0 to $310.0 for Cigna Group over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cigna Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cigna Group's significant trades, within a strike price range of $260.0 to $310.0, over the past month.
<h3>Cigna Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743188458_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.2</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$310.00</td>
<td>$171.5K</td>
<td>1.4K</td>
<td align="right">206</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.0</td>
<td>$10.6</td>
<td>$11.0</td>
<td>$310.00</td>
<td>$110.0K</td>
<td>1.4K</td>
<td align="right">406</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.4</td>
<td>$11.3</td>
<td>$11.3</td>
<td>$310.00</td>
<td>$56.5K</td>
<td>1.4K</td>
<td align="right">806</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.4</td>
<td>$11.3</td>
<td>$11.3</td>
<td>$310.00</td>
<td>$56.5K</td>
<td>1.4K</td>
<td align="right">756</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.3</td>
<td>$10.6</td>
<td>$11.3</td>
<td>$310.00</td>
<td>$56.5K</td>
<td>1.4K</td>
<td align="right">706</td>
</tr>
</tbody>
</table>

<h3>About Cigna Group</h3>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.
<h3>Current Position of Cigna Group</h3>
<ul>
<li>With a volume of 463,723, the price of CI is down -0.06% at $324.54. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 34 days.</li>
</ul>
<h3>What Analysts Are Saying About Cigna Group</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $365.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on Cigna Group, maintaining a target price of $365. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cigna Group, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Cigna Group Options Trading: A Deep Dive into Market Sentiment

Politics

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Bloomberg: 'A Senate panel backed Mehmet Oz to lead the Centers for Medicare and Medicaid Services, sending his nomination to the full chamber for a final vote.'

In the latest quarter, 12 analysts provided ratings for Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Cigna Group, revealing an average target of $366.0, a high estimate of $390.00, and a low estimate of $339.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.16%. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508078_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Cigna Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$365.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$375.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$341.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$390.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$348.00</td>
<td>$394.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$375.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$360.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Raj Kumar</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$379.00</td>
<td>$403.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$339.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$390.00</td>
<td>$420.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cigna Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cigna Group compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Cigna Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Cigna Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cigna Group analyst ratings.</a>
<h2>All You Need to Know About Cigna Group</h2>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.
<h3>Cigna Group: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Cigna Group's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 28.66%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cigna Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.17%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cigna Group's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.43%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Cigna Group's ROA excels beyond industry benchmarks, reaching 0.91%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.78.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Cigna Group Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

Cantor Fitzgerald analyst Sarah James maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $350 to $365.

Price Target

Cantor Fitzgerald Maintains Overweight on Cigna Group, Raises Price Target to $365

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 20 years by 4.58% on an annualized basis producing an average annual return of 12.74%. Currently, Cigna Group has a market capitalization of $87.45 billion. 
Buying $1000 In CI: If an investor had bought $1000 of CI stock 20 years ago, it would be worth $11,003.74 today based on a price of $322.56 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742397310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Cigna Group 20 Years Ago Would Be Worth Today

The Company is also reaffirming 2025 Evernorth pre-tax adjusted income from operations of at least $7.2 billion, and Cigna Healthcare pre-tax adjusted income from operations of at least $4.1 billion.

Guidance

Cigna Reaffirms 2025 Financial Outlook For Consolidated Adjusted EPS From Operations Of At Least $29.50, Est $29.92

Management

Cigna Names Brian Evanko As President And COO; Ann Dennison As CFO

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 15 years by 4.88% on an annualized basis producing an average annual return of 15.87%. Currently, Cigna Group has a market capitalization of $86.87 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 15 years ago, it would be worth $908.11 today based on a price of $317.43 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741723226_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Cigna Group 15 Years Ago Would Be Worth This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$35.00</td>
<td>$43.0K</td>
<td>680</td>
<td>1.7K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$815.00</td>
<td>$26.5K</td>
<td>38</td>
<td>268</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$62.50</td>
<td>$125.9K</td>
<td>90</td>
<td>253</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$360.00</td>
<td>$119.2K</td>
<td>472</td>
<td>203</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$210.00</td>
<td>$95.5K</td>
<td>290</td>
<td>193</td>
</tr>
<tr>
<td>IQV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$180.00</td>
<td>$200.2K</td>
<td>31</td>
<td>111</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$490.00</td>
<td>$99.7K</td>
<td>92</td>
<td>77</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$165.00</td>
<td>$26.6K</td>
<td>6.1K</td>
<td>56</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$330.00</td>
<td>$80.8K</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$600.00</td>
<td>$101.9K</td>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 37 day(s) on April 17, 2025. This event was a transfer of 426 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $101.0 per contract. There were 680 open contracts at this strike prior to today, and today 1750 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be neutral, expiring in 3 day(s) on March 14, 2025. This event was a transfer of 20 contract(s) at a $815.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $1325.0 per contract. There were 38 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option sweep that happens to be bearish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 221 contract(s) at a $62.50 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $125.9K, with a price of $570.0 per contract. There were 90 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option trade that happens to be bearish, expiring in 10 day(s) on March 21, 2025. This event was a transfer of 200 contract(s) at a $360.00 strike. The total cost received by the writing party (or parties) was $119.2K, with a price of $596.0 per contract. There were 472 open contracts at this strike prior to today, and today 203 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bullish, expiring in 31 day(s) on April 11, 2025. This event was a transfer of 193 contract(s) at a $210.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $95.5K, with a price of $495.0 per contract. There were 290 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding IQV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), we observe a put option sweep with bullish sentiment. It expires in 283 day(s) on December 19, 2025. Parties traded 110 contract(s) at a $180.00 strike. This particular put needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $200.2K, with a price of $1820.0 per contract. There were 31 open contracts at this strike prior to today, and today 111 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 23 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $99.7K, with a price of $4335.0 per contract. There were 92 open contracts at this strike prior to today, and today 77 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bullish sentiment. It expires in 101 day(s) on June 20, 2025. Parties traded 35 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $760.0 per contract. There were 6139 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $330.00 strike. The total cost received by the writing party (or parties) was $80.8K, with a price of $3110.0 per contract. There were 14 open contracts at this strike prior to today, and today 29 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with neutral sentiment. It expires in 464 day(s) on June 18, 2026. Parties traded 10 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $101.9K, with a price of $10193.0 per contract. There were 0 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Cigna Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) short percent of float has fallen 11.26% since its last report. The company recently reported that it has 3.67 million shares sold short, which is 1.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cigna Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741095057_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cigna Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cigna Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cigna Group's peer group average for short interest as a percentage of float is 9.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Cigna Group?

Cigna Officials Expect To Reaffirm Projected Full Year 2025 Consolidated Adjusted EPS Of At Least $29.50, Est $29.92

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$42.00</td>
<td>$33.4K</td>
<td>6.5K</td>
<td>5.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$27.00</td>
<td>$47.3K</td>
<td>322</td>
<td>2.3K</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$65.00</td>
<td>$28.0K</td>
<td>11.9K</td>
<td>672</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$87.00</td>
<td>$30.2K</td>
<td>6</td>
<td>500</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$43.00</td>
<td>$41.2K</td>
<td>5.7K</td>
<td>81</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$56.9K</td>
<td>1.9K</td>
<td>80</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$915.00</td>
<td>$32.2K</td>
<td>177</td>
<td>66</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$30.00</td>
<td>$34.0K</td>
<td>6.0K</td>
<td>50</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$520.00</td>
<td>$58.0K</td>
<td>962</td>
<td>40</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$310.00</td>
<td>$53.0K</td>
<td>38</td>
<td>19</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option trade that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $42.00 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $334.0 per contract. There were 6534 open contracts at this strike prior to today, and today 5139 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bearish sentiment. It expires in 29 day(s) on March 28, 2025. Parties traded 720 contract(s) at a $27.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $47.3K, with a price of $65.0 per contract. There were 322 open contracts at this strike prior to today, and today 2378 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option sweep that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $65.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 11949 open contracts at this strike prior to today, and today 672 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a put option trade that happens to be bearish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 144 contract(s) at a $87.00 strike. The total cost received by the writing party (or parties) was $30.2K, with a price of $210.0 per contract. There were 6 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a call option trade that happens to be bullish, expiring in 323 day(s) on January 16, 2026. This event was a transfer of 25 contract(s) at a $43.00 strike. The total cost received by the writing party (or parties) was $41.2K, with a price of $1650.0 per contract. There were 5751 open contracts at this strike prior to today, and today 81 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 323 day(s) on January 16, 2026. Parties traded 67 contract(s) at a $230.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $56.9K, with a price of $850.0 per contract. There were 1944 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with neutral sentiment. It expires in 8 day(s) on March 7, 2025. Parties traded 15 contract(s) at a $915.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $2150.0 per contract. There were 177 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
• Regarding BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we observe a call option trade with bullish sentiment. It expires in 78 day(s) on May 16, 2025. Parties traded 50 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $680.0 per contract. There were 6077 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bearish sentiment. It expires in 113 day(s) on June 20, 2025. Parties traded 10 contract(s) at a $520.00 strike. The total cost received by the writing party (or parties) was $58.0K, with a price of $5800.0 per contract. There were 962 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 204 day(s) on September 19, 2025. This event was a transfer of 19 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $53.0K, with a price of $2790.0 per contract. There were 38 open contracts at this strike prior to today, and today 19 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBIO

DXCM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

SWTX

Shares of major healthcare companies such as The Cigna Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) and UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) dropped Wednesday following the signing of an executive order by President Donald Trump aimed at strengthening price transparency regulations <a href="https://www.benzinga.com/insights/options/25/02/43981978/10-health-care-stocks-whale-activity-in-todays-session">in the industry.</a>
What To Know: The order, signed on Feb. 25, directs federal agencies, including the Departments of Treasury, Labor and Health and Human Services, to enforce and expand a 2019 rule that requires hospitals and insurers to publicly disclose the actual costs of medical services. This initiative seeks to eliminate price secrecy and provide consumers with clearer information on healthcare expenses according to Reuters.
The original 2019 rule required hospitals to display pricing information for up to 300 shoppable services in a consumer-friendly format and maintain a machine-readable file of negotiated rates for every service provided. Additionally, health insurance companies were mandated to disclose their negotiated rates with healthcare providers, their out-of-network payments, and the actual costs they or their pharmacy benefit managers pay for prescription drugs.
The renewed push for transparency has raised concerns among investors that stricter enforcement could impact revenue streams for hospitals and insurers. With healthcare companies required to publish actual prices rather than estimates, there is speculation that insurers may face increased pressure to negotiate lower rates with providers, potentially affecting profit margins. 
Price Action: The Cigna Group shares were down 2.27% to $306.77, Molina Healthcare shares dropped 7.95% to $281.65 and UnitedHealth Group shares declined 1.89% to $461.50 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43987636/bitcoin-tumbles-below-85000-amid-president-trumps-eu-tariff-threats">Bitcoin Tumbles Below $85,000 Amid President Trump&#8217;s EU Tariff Threats</a></li>
</ul>
Image via Shutterstock.

Movers

Healthcare Stocks Decline After Trump Signs Executive Order On Price Transparency

WIIM

Shares of healthcare stocks are trading lower after President Trump signed an executive order on healthcare price transparency.

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 15 years by 4.07% on an annualized basis producing an average annual return of 15.82%. Currently, Cigna has a market capitalization of $85.94 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 15 years ago, it would be worth $911.44 today based on a price of $313.90 for CI at the time of writing.
<h3>Cigna's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740518109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Financial giants have made a conspicuous bearish move on Cigna. Our analysis of options history for Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) revealed 16 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 68% showed bearish tendencies. Out of all the trades we spotted, 13 were puts, with a value of $1,308,898, and 3 were calls, valued at $247,758.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $270.0 to $310.0 for Cigna over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Cigna's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cigna's whale trades within a strike price range from $270.0 to $310.0 in the last 30 days. 
<h3>Cigna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740421844_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.2</td>
<td>$6.9</td>
<td>$7.9</td>
<td>$295.00</td>
<td>$713.3K</td>
<td>0</td>
<td align="right">149</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$10.3</td>
<td>$9.5</td>
<td>$9.6</td>
<td>$300.00</td>
<td>$172.0K</td>
<td>207</td>
<td align="right">1</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$23.3</td>
<td>$23.1</td>
<td>$23.18</td>
<td>$310.00</td>
<td>$111.0K</td>
<td>1.6K</td>
<td align="right">0</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.3</td>
<td>$7.9</td>
<td>$8.1</td>
<td>$292.50</td>
<td>$90.7K</td>
<td>0</td>
<td align="right">91</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$23.2</td>
<td>$22.1</td>
<td>$23.2</td>
<td>$310.00</td>
<td>$88.1K</td>
<td>1.6K</td>
<td align="right">50</td>
</tr>
</tbody>
</table>

<h3>About Cigna</h3>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.
After a thorough review of the options trading surrounding Cigna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Cigna's Current Market Status</h3>
<ul>
<li>Trading volume stands at 716,139, with CI's price up by 0.89%, positioned at $302.49.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 66 days.</li>
</ul>
<h3>What The Experts Say On Cigna</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $368.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Cigna, maintaining a target price of $375. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Cigna, which currently sits at a price target of $390. 
&#x2A; An analyst from Piper Sandler downgraded its action to Overweight with a price target of $348. 
&#x2A; Consistent in their evaluation, an analyst from Stephens &amp; Co. keeps a Overweight rating on Cigna with a target price of $380. 
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Cigna with a target price of $350. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cigna options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Cigna Options Trading: A Deep Dive into Market Sentiment

The Justice Department has reportedly launched a civil fraud investigation into UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Medicare billing practices.
The probe began in recent months and will examine UnitedHealth&#8217;s Medicare Advantage plans and physician groups following reports that the company received billions in federal payments for questionable diagnoses.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43065141/analysts-maintain-optimism-for-unitedhealth-despite-mixed-q4-results" rel="noreferrer noopener">UnitedHealth&#8217;s Strong Member Loyalty Powers Analyst Growth Forecasts</a>
The insurance giant is already under scrutiny. In January, the Federal Trade Commission released a second interim staff report detailing significant price markups on specialty generic drugs by&nbsp;UnitedHealth&#8217;s pharmacy benefit management unit along with&nbsp;CVS Health Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) CVS Caremark and&nbsp;Cigna Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43010888/ftc-says-unitedhealth-cvs-cigna-make-billions-via-pbms-on-specialty-drugs" rel="noreferrer noopener">Express Scripts</a>.
The Wall Street Journal <a target="_blank" href="https://www.wsj.com/health/healthcare/unitedhealth-medicare-doj-diagnosis-investigation-66b9f1db?mod=latest_headlines" rel="noreferrer noopener">reported</a> that Medicare paid UnitedHealth substantial sums based on diagnoses added to patients&#8217; records, some of which doctors said were irrelevant or undocumented.
The WSJ report&#8217;s analysis of Medicare data from 2019 to 2021 found that UnitedHealth-employed doctors significantly increased the number of lucrative diagnoses for patients in the company&#8217;s Medicare Advantage plans.
Additionally, some diagnoses were added without physician treatment, including through in-home nurse visits, leading to an extra $8.7 billion in federal payments in 2021.
Each visit by UnitedHealth-employed nurses was valued at an average of $2,735 in additional government reimbursements.
The WSJ report added that UnitedHealth has defended its Medicare billing practices, arguing that they lead to more accurate diagnoses, improve patient care, and reduce healthcare costs. The company has previously stated that it performs well in Medicare audits and has disputed the Journal&#8217;s findings.
UnitedHealthcare, one of the largest health insurers in the U.S. with over 50 million members, has faced ongoing criticism over its <a target="_blank" href="https://www.benzinga.com/24/12/42365853/unitedhealthcare-faces-tough-questions-following-insurance-business-ceos-tragic-death" rel="noreferrer noopener">claim denial practices</a>.
A Senate investigation earlier this year concluded that Medicare Advantage providers, including UnitedHealthcare, intentionally denied claims to increase profits.
As per a recent media report, UnitedHealthcare, the insurance arm of&nbsp;UnitedHealth, is reportedly offering some employees in its benefits operations unit a chance to take a buyout if they <a target="_blank" href="https://www.benzinga.com/25/02/43829064/unitedhealthcare-offers-voluntary-buyouts-possible-layoffs-if-targets-not-met-cnbc" rel="noreferrer noopener">resign by March 3</a>.
In a social media <a target="_blank" href="https://x.com/BillAckman/status/1892912458840547554" rel="noreferrer noopener">post</a>, investor Bill Ackman said,&#8221; When a company, in this case United Healthcare, attacks its critics, the probability that it has committed fraud or is guilty of a crime increases substantially.&#8221;
&#8220;My psychological short here is paying off and I would avoid this stock,&#8221; Ackman added.
Price Action: UNH stock was down 10.2% at $451.36&nbsp;during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43851537/centerpoint-energy-stays-on-track-eps-rises-25-grid-upgrade-planned-and-more" target="_blank" rel="noreferrer noopener">CenterPoint Energy Stays On Track: EPS Rises 25%, Grid Upgrade Planned And More</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock.com

Media

DOJ Investigates UnitedHealth, Probe Accuses Of Inflating Medicare Diagnoses

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 20 years by 3.61% on an annualized basis producing an average annual return of 11.95%. Currently, Cigna has a market capitalization of $78.60 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 20 years ago, it would be worth $963.37 today based on a price of $287.08 for CI at the time of writing.
<h3>Cigna's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738960209_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Truist Securities analyst David Macdonald maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and lowers the price target from $390 to $375.

Comments

Cigna Group

ニュース

パートナーシップ

ベンジンガ・グローバル